Stay updated on IGN002 Dose-Escalation Study in NHL Clinical Trial
Sign up to get notified when there's something new on the IGN002 Dose-Escalation Study in NHL Clinical Trial page.

Latest updates to the IGN002 Dose-Escalation Study in NHL Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe page has a redesigned layout and styling, but core study details such as title, conditions, eligibility, outcomes, and locations remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check32 days agoChange Detected- Added a government-operations notice about potential delays and updated status; included links for details. - Updated software version from v3.1.0 to v3.2.0.SummaryDifference5%

- Check39 days agoChange Detected- Updated version from v3.0.2 to v3.1.0. - No other content changes detected.SummaryDifference0.1%

- Check53 days agoChange DetectedVersion updated from v3.0.1 to v3.0.2; the Back to Top link was removed. No other substantive changes detected.SummaryDifference0.3%

- Check60 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. Additionally, a 'Back to Top' feature has been added for improved navigation.SummaryDifference0.3%

- Check68 days agoChange DetectedThe web page has undergone significant changes, including the addition of a facility name and location related to Hemic and Lymphatic Diseases, while removing specific geographic details and resources related to Lymphosarcoma and Lymphoma.SummaryDifference3%

Stay in the know with updates to IGN002 Dose-Escalation Study in NHL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the IGN002 Dose-Escalation Study in NHL Clinical Trial page.